Importance COVID-19 has placed a monumental burden on the health care system globally.
Although no longer a public health emergency, there is still a pressing need for effective …

Objective: Develop models to predict 30-day COVID-19 hospitalization and death in the
Omicron era for clinical and research applications. Material and Methods: We used …

Background The MOVe-OUT (efficacy and safety of molnupiravir [MK-4482] in non-
hospitalized adult participants with COVID-19 [MK-4482-002]) trial reported that the …

Background We described the oral nirmatrelvir/ritonavir (NMV/r) and molnupiravir (MOV)
uptake among a subgroup of highly vaccinated adults in a US national prospective cohort …

Introduction: The coronavirus disease 2019 (COVID-19) pandemic started in March 2020.
Since then, there has been an urgent need for effective therapeutic methods to manage the …

Background: Molnupiravir is a ribonucleoside analog and exhibits its antiviral mechanism by
inhibiting replication. Preclinical studies have been reported that support the role of …

This review summarizes the current literature on antiviral drugs used in the treatment of
COVID-19. The pandemic caused by COVID-19 is an important cause of mortality and …

Background Comparative data on mortality in COVID-19 patients treated with molnupiravir
or with nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause …

After a downward trend for more than 12 months, the incidence of COVID-19 has increased
in the last months. Although COVID-19 is not as frequent as in the first years of the …

Objective To assess the real-world effectiveness of molnupiravir (MOL) in reducing the need
for hospitalization in at-risk, non-hospitalized patients with confirmed COVID-19. Methods A …